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Abstract
Background:  Appropriately formulated quantitative computational models can support
researchers in understanding the dynamic behaviour of biological pathways and support hypothesis
formulation and selection by "in silico" experimentation. An obstacle to widespread adoption of
this approach is the requirement to formulate a biological pathway as machine executable
computer code. We have recently proposed a novel, biologically intuitive, narrative-style modelling
language for biologists to formulate the pathway which is then automatically translated into an
executable format and is, thus, usable for analysis via existing simulation techniques.
Results: Here we use a high-level narrative language in designing a computational model of the
gp130/JAK/STAT signalling pathway and show that the model reproduces the dynamic behaviour
of the pathway derived by biological observation. We then "experiment" on the model by
simulation and sensitivity analysis to define those parameters which dominate the dynamic
behaviour of the pathway. The model predicts that nuclear compartmentalisation and
phosphorylation status of STAT are key determinants of the pathway and that alternative
mechanisms of signal attenuation exert their influence on different timescales.
Conclusion:  The described narrative model of the gp130/JAK/STAT pathway represents an
interesting case study showing how, by using this approach, researchers can model biological
systems without explicitly dealing with formal notations and mathematical expressions (typically
used for biochemical modelling), nevertheless being able to obtain simulation and analysis results.
We present the model and the sensitivity analysis results we have obtained, that allow us to identify
the parameters which are most sensitive to perturbations. The results, which are shown to be in
agreement with existing mathematical models of the gp130/JAK/STAT pathway, serve us as a form
of validation of the model and of the approach itself.
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Background
Biological signalling pathways of even modest complexity
cannot be comprehensively analysed within a feasible
timescale by currently available experimental tools. How-
ever appropriate pathway models can be used to generate,
explore and refine hypotheses guiding the formulation
and prioritisation of experimental interventions. This has
conventionally been approached by the use of models
inspired by chemical kinetics and articulated mathemati-
cally in the form of ordinary differential equations.
Recently an alternative approach, "molecules as computa-
tion", has been proposed in which a pathway is formu-
lated as an executable computer programme [1,2] which
can be interrogated to determine the dynamic behaviour,
robustness and parameter sensitivities of the model [3].
The outcomes of in silico experimentation on the compu-
ter model can then be used to inform the design of biolog-
ical interventions in vitro. Among the various
computational languages which have been used to model
biochemical systems, we consider here process calculi (see
for example [4-8], or [9] for a review of the process calculi
approach). These calculi are formal languages which
allow modellers to perform several kinds of analyses on
the models (e.g. model-checking, causality and equiva-
lence analysis).
One key challenge of this approach is the accurate descrip-
tion of biological pathways in the form of an executable
computer language. From the biologist's perspective the
formulation has to capture the biologically interesting fea-
tures of the pathway and be readily understood by other
biologists. From the computer scientist's perspective the
formulation has to conform to the rules of formal meth-
ods in computer science: it must be logically precise and
unambiguous. There is therefore a potential language gap
between what the biologist understands and what the
computer model encodes. We have recently described a
high-level biologically-intuitive textual language in which
the signalling pathway is articulated in the form of a nar-
rative of events concerning the interactions between com-
ponents located in different compartments [10]. This
articulation of the pathway is then translated into an exe-
cutable computer programme (written in the process cal-
culus-based BlenX language [11]) for further analysis. In
this paper we describe, develop and interrogate such an
executable model of the gp130/JAK/STAT signalling path-
way [12] using the Narrative Language approach and
explore its predictions by in silico experimentation.
The gp130/JAK/STAT signalling pathway (see for example
[12]) is the subject of significant clinical and biological
interest, not least due to the key role it plays in human fer-
tility, neuronal repair, haematological development and
embryonic stem cell renewal [13]. Members of the gp130
cytokine family, such as LIF or OSM, bind to the common
signal transducing receptor chain gp130 and a second sig-
nalling receptor LIFR or OSMR [14]. Homo- or hetero-
dimerisation of gp130, LIFR and OSMR induces activation
of the receptor associated kinase JAK which in turn phos-
phorylates the latent transcription factor STAT which, as a
consequence, undergoes homo-dimerisation, translocates
to the nucleus and activates the transcription of down-
stream gene targets (Figure 1). Several features of this
pathway make it an attractive case study for a computer
programme based modelling approach. A characteristic
feature of the gp130/JAK/STAT system is the role of spatial
confinement in which the transcription factor STAT
undergoes nuclear/cytoplasmic shuttling which is regu-
lated by JAK-mediated phosphorylation at the plasma
membrane and T-Cell Protein Tyrosine Phosphatase (TC-
PTP)-mediated de-phosphorylation in the nucleus
[15,16]. Aside from gp130/JAK activation by ligand the
dynamics of the pathway can be regulated by a variety of
mechanisms, which include STAT-mediated induction of
Suppressor of Cytokine Signalling (SOCS) family pro-
teins, which suppress JAK activation [17] and the Protein
Inhibitor of Activated STAT (PIAS), an E3 family ubiquitin
ligase which induces proteolytic degradation of phospho-
STAT [18,19]. Chronic nuclear STAT activation and/or JAK
activation [20,21] have been implicated as a predisposing
event in a variety of tumour types indicating that pathway
dynamics have significant impact on cell behaviour. Elu-
cidating the relative influence of different pathway param-
eters on the activity of STAT will guide the evaluation of
therapeutic interventions.
Much experimental data is available on the gp130/JAK/
STAT pathway and several mathematical models have
been developed based on ordinary differential equations
(see for example [22-24]). We present a different
approach to modelling this pathway based on formal
computational methods. We use a novel textual language
for modelling biochemical systems [10], and perform
simulations through the BetaWB simulator [25], an exist-
ing tool based on Gillespie's stochastic simulation algo-
rithm [26]. A key feature of the formal computational
approach is the ability to rigorously explore, by in silico
experimentation, the dynamic behaviour of the model to
determine both the role of signal modifiers such as SOCS
and the importance of parameter values. We validate our
computational model by showing that it produces out-
puts which conform to those produced by experiment. We
then perform in silico experiments on the model to deter-
mine first and second order parameter sensitivities and
the effects of various types of pathway modulators. We
show that the dynamic behaviour of the pathway is dom-
inated by the rate of STAT de-phosphorylation and
nuclear export and that these two variables result in bista-
ble pathway behaviour when combined together in the
model.BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
Page 3 of 12
(page number not for citation purposes)
Methods
Narrative Modelling Language
For modelling the gp130/JAK/STAT pathway, we use the
Narrative Language, a high-level textual language which
has been recently designed for modelling dynamically reg-
ulated and spatially-confined biochemical pathways.
Here we introduce the main features of the Narrative Lan-
guage; for a detailed description of the language and of its
translation into an executable language, the reader is
referred to [10] and [27].
The basic entities of the language are molecules (compo-
nents) and sub-cellular locations (compartments). In the
language molecules can interact (e.g. bind/unbind),
undergo biochemical modification (e.g. phosphoryla-
tion/de-phosphorylation) and re-locate between com-
partments. The time-dependent behaviour of the pathway
is described in the form of a narrative of events involving
these basic entities and functions, which imposes a tem-
poral sequence and defines inter-dependencies and con-
tingencies. In the narrative approach each of the elements
can denote 'real' (i.e. experimentally defined) or abstract
(e.g. hypothetical) entities. In silico exploration of the
pathway model is simply enabled by modifying the narra-
tive description and/or changing parameter values.
A feature of this narrative approach is the use of reliability
values associated with numerical parameters. This is a per-
centage value which describes the reliability of the associ-
ated numerical value, and it can be used to distinguish
between values that are highly certain because obtained
from high quality biological experiment, and others
which are inferred as a result of un-verified assumptions
or 'guesswork' (e.g. 100% indicates high precision data,
while 0% indicates a value which has no experimental evi-
dence). Reliability values do not influence the behaviour
Graphical representation of the gp130/JAK/STAT pathway Figure 1
Graphical representation of the gp130/JAK/STAT pathway. Solid arrows represent biochemical reactions, dotted 
arrows represent transports, and dashed arrows represent syntheses. In the insert the different types of receptor complexes 
are shown.BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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of the programme but are annotations to inform use of
the model. In particular modellers can employ reliability
values to identify parameter dependencies to be explored
during model refinement.
Model description and simulation
The Narrative Language model of the gp130/JAK/STAT
signalling pathway is supplied as Additional files 1, 2, 3,
4, 5, 6, 7 and 8. The molecular components we consider
in the model are: two ligands (LIF and OSM), three mem-
brane-bound receptors (gp130, LIFR and OSMR), one
effector (STAT3), and two inhibitors (SOCS3 and PIAS3).
The receptor associated kinase JAK and TC-PTP phos-
phatase are implicitly modelled.
Additional file 2 shows the definition of the components
involved in the pathway. For each protein, the list of inter-
action/modification sites, states and locations are defined
and initialised. Each receptor contains at least one ligand
binding site (OSMR has only one site for OSM, while LIFR
and gp130 also have one site for LIF), one binding site for
SOCS3 inhibitor, and some phosphorylation sites. More-
over, receptors can be in dimeric state (an additional site
in gp130 allows us to distinguish between the two types
of OSM receptors). STAT3 has one phosphorylation and
four binding sites (for receptors and PIAS3 inhibitor), and
it can be monomeric or dimeric (STAT3 can form
homodimers). The initial quantities are also defined. The
number of ligands is calculated based on the known extra-
cellular concentration (500 pM).
Four compartments are involved in the system (see addi-
tional file 1): the exosol (the extracellular space, where the
ligands are located), the cell membrane (location of the
receptors), the cytosol (initial location of the STAT3 effec-
tor), and the nucleus (to which the effector can translo-
cate). The compartment volumes are calculated based on
the average cell radius and ratio between intra-cellular
compartment volumes stated in [28]. The number of spa-
tial dimensions is used to distinguish between 2D com-
partments (i.e. membranes) and 3D ones.
Additional file 3 shows the definition of the biochemical
reactions occurring in the pathway. Reaction types (e.g.
binding, unbinding, phosphorylation, relocation) and
rates (i.e. the kinetic constants) are defined here. The reac-
tion volume is the volume in which the reaction occurs
(generally it is the size of the compartment in which the
involved species are located), and it is used in deriving the
actual rate at which the reaction occurs. Some of the reac-
tion rates have been obtained from wet experiments,
while others have been estimated based on information
about similar reactions, or extracted from other models
[22-24]; reliability values are assigned to reaction rates
and volumes.
Finally, Additional files 4, 5, 6, 7 and 8 show the defini-
tion of the narrative of events, which describes the evolu-
tion of the system; it is a sequence of basic events, each of
which is a constrained textual description of a biochemi-
cal reaction involving at most two components. Moreo-
ver, events are grouped into processes for the sake of
readability. The defined events describe the binding/
unbinding of ligand/receptor pairs, the downstream LIF
and OSM pathways (formation and activation of receptor
complexes), the downstream STAT3 pathway (recruit-
ment and activation of STAT3, and its nuclear/cytoplas-
mic shuttling), and the inhibition mechanisms.
Additional file 4 models the binding of ligands to recep-
tors (reaction r1 in the graphical representation of the
pathway shown in Figure 1 and events 1, 3, 5, 7 and 9 in
the Narrative Language model), and the inverse unbind-
ing reaction (r2, events 2, 4, 6, 8 and 10). For each event,
the involved components and the occurring interaction
are specified (e.g. event 1 states that LIF binds to receptor
gp130 on a specific binding site) together with the activat-
ing conditions (e.g. for event 1, the binding site in gp130
is not already occupied, LIF itself is free, and gp130 is not
already in dimeric form), and the reference to the corre-
sponding reaction in Additional file 3.
Additional file 5 models the dimerisation of pairs of
receptor subunits to form receptor complexes (gp130-
LIFR or gp130-OSMR), which is triggered by the binding
of a ligand to one of the receptors (r3, events 11, 13, 15,
17, 19 and 21) (e.g., in events 19 and 21, OSMR and
gp130 form a heterodimeric complex if one of them has
been previously activated by ligand binding); the dissoci-
ation of the receptor complexes is also modelled (r4,
events 12, 14, 16, 18, 20 and 22).
Additional file 6 models the activation (JAK-mediated
phosphorylation) of the receptor complexes, the binding
of STAT3 to a receptor complex, and the activation (phos-
phorylation) of STAT3. Once the receptor dimeric com-
plex is formed, each receptor subunit (gp130, LIFR and
OSMR) can phosphorylate on specific sites (r5, events 23,
25, 27 and 29). STAT3 can bind on receptors' phosphor-
ylated sites (r7, events 31, 32 and 33), and the binding of
STAT3 allows the phosphorylation of STAT3 on site Y705
(r8, events 37, 38 and 39).
Additional file 7 models the unbinding of STAT3 from
receptor complexes, its homodimerisation, and nuclear/
cytoplasmic shuttling (relocation into the nucleus, de-
phosphorylation by TC-PTP, de-homodimerisation and
relocation into the cytoplasm). Once phosphorylated,
STAT3 can dissociate from the receptor complex (r10,
events 41, 42 and 43); the phosphorylated site allows
STAT3 to homodimerise (r11, event 44). When STAT3 isBMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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in dimeric form, it can translocate into the nucleus (r12,
event 45) where it can carry out its specific functions (not
modelled here): STAT3 binds to the DNA, activating the
transcription of downstream gene targets. Nuclear STAT3
is inactivated through de-phosphorylation by TC-PTP
(r13, event 46), which leads to its de-dimerisation (r14,
event 47), and its export to the cytoplasm (r15, event 48),
where STAT3 can undergo additional cycles of activation.
Additional file 8 models SOCS3 and PIAS3 inhibition
mechanisms. SOCS3 is produced by active STAT3 (r16,
event 49) and degraded (event 50), and it acts by compet-
ing with STAT3 in binding to receptors (r17, events 51, 52
and 53). PIAS3 acts by binding to active nuclear STAT3
(r18, event 57).
We developed a tool [29], N2BB, which implements an
automatic translation of models described in the biologi-
cally-intuitive Narrative Language into executable com-
putable models formulated in BlenX [11], a programming
language inspired on the Beta-binders process calculus [4].
Process calculi, originally developed for modelling
mobile communicating systems, have recently been pro-
posed as appropriate for simulating biological processes
[1], and they have proved themselves as powerful tools for
dynamical modelling of complex biological systems [5-8].
Differently from differential equations, process calculi
also allow for analysis of models (e.g. model-checking,
equivalence, reachability, causality, and locality analysis).
The BlenX model derived from the Narrative Language
model is compatible with the BetaWB [25], a collection of
tools for modelling, simulating, and analysing BlenX
models. Hence, the model can be imported into the
BetaWB designer, or directly simulated by means of the
BetaWB simulator; the time-evolution of the simulation
can be visualised by means of the BetaWB plotter or the
Snazer tool [30]. For a detailed description of the BlenX
language and of the implementation of the simulator, see
[25,11].
Cells, reagents and cytokines
MCF-7 human breast cancer cells were obtained from
American Type Culture Collection (Manassas, VA) and
cultured as described [13]. The human oncostatin M
recombinant expression plasmid, pGEX-3C-OSM, was
prepared, expressed and purified as described previously
[13].
Western blot, immunofluorescence and data analysis
Serum starved MCF-7 cells were stimulated with 10 ng/ml
oncostatin M for increasing times (up to 480 minutes) at
37°C. For Western blot analysis, cell lysates were prepared
and analysed as described [13] and monoclonal anti-
phospho STAT3 (Tyr705) and STAT3 (Cell Signalling
Technology) antibodies used for immunodetection. The
density of the bands representing phospho-STAT3 and
STAT3 were measured using ImageJ [31] and expressed as
the ratio of phospho-STAT3 to STAT3. For immunofluo-
rescence studies, MCF7 cells grown on coverslips were
fixed with 4% paraformaldehyde (10 min, RT), permeabi-
lised with 0.1% saponin solution (0.02 M glycine, 0.1%
saponin, 0.1 M Tris/HCl pH8.5) for 20 min and blocked
for 1 hour in 0.1% saponin solution (0.1% saponin, 0.1
M Tris/HCl pH8.5) plus 2.5% foetal calf serum. Cells were
immunostained with monoclonal anti-STAT3 antibody
for 1 h at RT and incubated with Texas Red-conjugated
secondary antibody containing Hoechst (Molecular
Probes) for 45 min at RT. Coverslips were mounted with
5 μl of Mowiol solution (10% Mowiol 4–88, 25% glyc-
erol, 0.1 M Tris/HCl pH8.5) on the slide and observed
under confocal microscope. For localisation analysis,
images captured were converted to greyscale and total
STAT3 fluorescence calculated from the sum of pixel den-
sity values using ImageJ. Nuclear STAT3 fluorescence was
calculated from selection of nuclear area (as determined
by Hoechst staining) and cytoplasmic STAT3 fluorescence
calculated by subtracting nuclear staining from total cellu-
lar staining. For each time-point analysis was performed
on between 60 – 100 cells (from multiple coverslips) and
mean values ± 2 SD were calculated for total nuclear and
cytoplasmic STAT (expressed as percentage of total STAT).
Results and discussion
We used the N2BB tool to automatically translate the
gp130/JAK/STAT pathway model into BlenX and we sim-
ulated the derived model using the BetaWB. Our intention
in the simulations that follow was to firstly define the
behaviour of the full model and then to study the behav-
iour of the model in response to perturbations such as
modifying numerical values and/or removing compo-
nents from the model. A particular feature of the narrative
approach is that it is very simple to change parameters or
modify the narrative of events in the process of model
exploration.
Our aim is to define those features, which exert the dom-
inating influence on the dynamic behaviour of the path-
way in the model for evaluation by biological experiment.
This is an example of using computer models to explore a
wide range of scenarios in silico to guide the formulation
of the more laborious and expensive laboratory-based
experiments.
The time-evolution resulting from the simulation of the
model is shown in the following pictures. Figure 2A
reports the time-evolution of the full model, while Figure
2B–2D show the evolution when different inhibitors are
removed (in silico genetics). The amounts of different
STAT3 forms are plotted: monomeric cytoplasmic,BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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dimeric cytoplasmic, monomeric nuclear, and dimeric
nuclear.
Figure 2A shows that in the initial configuration STAT3 is
present in monomeric form in the cytoplasm. As the sys-
tem undergoes dynamic evolution, STAT3 is rapidly phos-
phorylated, dimerised and translocated into the nucleus.
At the same time cytoplasmic STAT3 is dramatically
reduced. The system reaches a plateau for some time and
then slowly reverses as nuclear STAT3 levels fall and cyto-
plasmic levels rise. This behaviour conforms well to that
obtained experimentally by observing the time-evolution
of STAT3 phosphorylation (Additional file 9) and the
relocation of STAT3 to the nuclear compartment in
response to gp130 activation (Additional file 10). How-
ever it is important to note that, whilst the model and
experimental data are in quantitative agreement for early
time points (0–200 minutes), the experimental data
reveals a faster rate of recovery of cytoplasmic STAT3 than
predicted from the model over longer time periods. We
were unable to accelerate the rate of relocalisation of
STAT3 in the model by parameter variation (data not
shown) which we interpret as indicating that the current
model does not include biological processes that influ-
ence the rate of nuclear/cytoplasmic shuttling at later time
points. In this context we remark that the current model
takes no account of the induction of new gene expression
[13] by gp130 signalling over this time period which
could include components that influence the rate of
nuclear/cytoplasmic transfer.
Role of inhibitors in the gp130/JAK/STAT pathway Figure 2
Role of inhibitors in the gp130/JAK/STAT pathway. (A) Full model. (B) SOCS3 knock out. (C) PIAS3 knock out. (D) TC-
PTP knock out. For each experiment the amounts of different STAT3 forms are plotted: monomeric cytoplasmic (STAT3-C), 
dimeric cytoplasmic (STAT3-PDC), monomeric nuclear (STAT3-N), and dimeric nuclear (STAT3-PDN).BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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We conclude that the computer model derived from the
original narrative is able to capture the dynamic behav-
iour of the real pathway, demonstrating the validity of the
approach.
In the next phase we explored the dependency of the
model on the presence of various components which were
'knocked out' by removal from the programme.
By comparing Figure 2A and 2B, in which we run the sim-
ulation in the absence of SOCS3, we observe that the
effect of SOCS3 expression in response to STAT3 activa-
tion is to activate the slow attenuation process observed in
the full model: removal of SOCS3 suppresses the delayed
re-appearance of cytoplasmic STAT3 and the pathway
exhibits prolonged and stable nuclear occupancy of
STAT3.
The role PIAS3, which binds to phosphorylated nuclear
STAT3 preventing it binding to DNA, is revealed by com-
paring Figure 2A and 2C. In this case removal of PIAS3
yields an initial increase of active STAT3, but the nuclear
STAT3 signal attenuates with a faster time-course than in
the full model, leading to an increase in cytoplasmic (and
therefore inactive) STAT3.
Figure 2D shows the outcomes of removing the nuclear
phosphatase TC-PTP from the model. In this case there is
a rapid accumulation of nuclear STAT3 which reaches
steady state and fails to attenuate. In this case cytoplasmic
STAT3 is rapidly eliminated and does not re-appear.
Comparing the consequences of removing three different
types of inhibitor from the model it is clear that each has
characteristic temporal effects. The consequences of TC-
PTP inhibition are significantly more rapid than removal
of SOCS3 or PIAS3. Inhibition of SOCS3 and TC-PTP lead
to prolonged and stable activated STAT3, whereas inhibi-
tion of PIAS3 accelerates the rate of activated STAT3 decay
by inducing accumulation of cytoplasmic STAT3.
Single parameter sensitivity analysis
We next turned to analysis of the parameter sensitivities of
the model. In this case we ran simulations in which indi-
vidual parameters were systematically varied to observe
the dependency of model behaviour on individual values.
The aim here is to define those values, which have greatest
impact on model behaviour.
We first examined the dependency of the model on the
amount of STAT3 in the system. In this case we ran simu-
lations containing different numbers of STAT3 molecules
at initialisation (Figure 3). We observe that the duration
of nuclear occupancy is relatively stable to STAT3 pertur-
bation until it drops below a threshold value (in this case
between 30–300 molecules) when it collapses into
'noise'. However the number of STAT3 molecules had a
significant effect on peak amplitude where there was an
approximately linear relationship between the maximum
number of activated STAT3 molecules reached and the
total number of molecules in the system.
We next examined the rate of TC-PTP de-phosphoryla-
tion, the amount of ligand, the rate of JAK kinase phos-
phorylation and the rate of nuclear export (Figure 4A–
4D). The outcomes of these simulations show that the
behaviour of the model is differentially dependent on par-
ticular values.
Slowing the rate of phospho-STAT3 de-phosphorylation
exhibited significant effects on activated STAT3 amplitude
and duration noted over the complete range analysed
(Figure 4C). De-phosphorylation rates impacted on both
the peak amplitude and duration of activated STAT3 indi-
cating, as reported by others [32], that nuclear de-phos-
phorylation of activated STAT3 is an important
determinant of signalling dynamics. Similar sensitivities
were found on varying the rate of nuclear export (Figure
4D): although in this case nuclear export had no impact
on peak signal amplitude and its main effect was on signal
duration.
By contrast the model was relatively robust to variations
in either the amount of ligand in the system or the rate of
JAK activation (Figure 4A and 4B) where significant
impacts on signal dynamics only become apparent at
extreme values. Indeed, similar to the dependency on
STAT3 numbers, it appears as though behaviour of the
model is relatively robust to parameter changes in these
processes over several orders of magnitude.
Multi-dimensional parameter sensitivity
The foregoing in silico experiments revealed that the
dynamic behaviour of the gp130/JAK/STAT pathway is
most sensitive to two parameters: the rate of nuclear
STAT3 de-phosphorylation and the rate of STAT3 nuclear
export. We were interested to learn if the model exhibited
higher order dependencies when parameters were varied
in combinations. Exhaustive implementation of this
approach is currently computationally expensive. For this
study we therefore chose to study the interaction between
nuclear de-phosphorylation of STAT3 and export of de-
phosphorylated STAT3. To this end 35 simulations were
run in which each parameter was changed simultaneously
(Figure 5). The results of this experiment were surprising.
Instead of exhibiting a graded response across the whole
parameter landscape, as might be predicted from the
behaviour of each individual value, the system exhibits a
bistable response in which, for the majority of conditions,
the system is either constitutively activated or constitu-BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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tively repressed. The system only exhibits sensitivity to
parameter variation in a narrow region of values towards
the middle of the ranges chosen. In this region both peak
amplitude and signal duration were dependant upon the
interplay between nuclear export and STAT3 de-phospho-
rylation.
Conclusion
Our purpose in this study was to explore the practical util-
ity of the biological narrative approach for in silico explo-
ration of a complex signalling pathway. We used the
gp130/JAK/STAT pathway as a case study, and we showed
that the biologist-specified narrative yields outcomes
which conform well to experimental data. By 'experiment-
ing' on the model by parameter exploration and compo-
nent removal we were able to explore the influence of
different elements on the dynamic behaviour of the path-
way. Some of these experiments had already been per-
formed in previous works [22-24], and the results we
obtained show a good agreement with them; others pro-
vide novel insight on the pathway behaviour. Our analy-
ses showed that the rate of STAT nuclear export and
nuclear localised de-phosphorylation were key determi-
nants of signalling dynamics. This conclusion is sup-
ported by in vitro experimental data in which inhibition
of nuclear export by either drug treatment [33,34] or
mutation of the Nuclear Export Sequence [35] results in
prolonged nuclear accumulation of phosphorylated STAT.
The dependency of STAT import/export is also in agree-
ment with existing mathematical models of the same
pathway [22-24].
This outcome indicates that the model captures the
dynamic behaviour of the real pathway well and encour-
Single parameter sensitivity analysis: variation of STAT3 initial amount Figure 3
Single parameter sensitivity analysis: variation of STAT3 initial amount. The evolution of the system has been 
observed varying the initial amount of STAT3. (A) 30 molecules. (B) 300 molecules. (C) 3000 molecules. (D) 30000 molecules. 
The amount of active nuclear STAT3 (STAT3-PDN) is plotted.BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
Page 9 of 12
(page number not for citation purposes)
ages further exploration of the model into issues which
would be resource intensive – or technically challenging –
to address by biological experimentation. In particular we
were interested in exploring the potential for interactions
between parameters which are not currently addressable
by biological experiment. We found, combining nuclear
export and nuclear de-phosphorylation, that the two
parameters interact strongly yielding a 'switch-like' behav-
iour. This type of modelling analysis may inform future
considerations of multi-step mutagenesis or combination
drug therapy scenarios in the gp130/JAK/STAT pathway.
The identified interaction between nuclear export and
nuclear de-phosphorylation is novel, and the obtained
behaviour was unpredicted; the insensitivity to the rate of
JAK phosphorylation is another interesting outcome.
These novel results reinforce our belief about the predic-
tive power of this kind of modelling approach. In order to
be validated, the hypotheses deriving from our simulation
results should be tested by means of specific laboratory
experiments. For instance, the characteristic dynamic
shifts exhibited when the three inhibitors are removed
from the system could be tested using appropriate mutant
cells or by the use of specific pharmacological inhibitors.
However, in general this might not be a simple task
because it often involves the generation of such cells/
drugs.
We have demonstrated in this study that a language can be
used to describe biological signalling pathways in a way,
which is formal and unambiguous for computational exe-
cution but more intuitive to the biologist compared with
standard modelling languages. The approach exploits the
particular advantages of the "molecule as computation"
Single parameter sensitivity analysis Figure 4
Single parameter sensitivity analysis. The evolution of the system has been observed varying each parameter individually. 
(A) Ligands initial amount. (B) JAK-mediated phosphorylation. (C) TC-PTP-mediated de-phosphorylation. (D) Nuclear export. 
The amount of active nuclear STAT3 (STAT3-PDN) is plotted.BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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paradigm of Regev and Shapiro [1]: the resulting models
are computable, relevant and understandable. There are
also practical advantages to process calculus models in
that they can be readily modified to explore different sce-
narios and interrogated using model-checking tools [3] to
formally verify the model and explore its quantitative
behaviour. Collectively the approach is therefore extensi-
ble in that, as new biological information on the pathway
becomes available, it can be readily incorporated into the
model.
In addition to the advantage of being simpler to use for
modelling compared to directly specifying models in for-
mal languages such as process calculi, the Narrative Lan-
guage also provides modellers with a number of explicit
features which capture some cardinal aspects of biological
signalling pathways. It defines the temporal relationships
between events (i.e. sequential, concurrent and compet-
ing events). It defines the location of proteins and the
reaction volumes, and it deals with multi-compartmental
models thereby making spatial location and confinement
Multi-dimensional parameter sensitivity Figure 5
Multi-dimensional parameter sensitivity. The evolution of the system has been observed varying simultaneously the rate 
of nuclear STAT3 de-phosphorylation and the rate of STAT3 nuclear export. The considered values are as in Figure 4C and 
4D. The rows (A-G) refer to the export rate, while the columns (i-v) refer to the de-phosphorylation rate. The amounts of 
active nuclear STAT3 (STAT3-PDN) and monomeric nuclear STAT3 (STAT3-N) are plotted.BMC Systems Biology 2009, 3:40 http://www.biomedcentral.com/1752-0509/3/40
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a central feature. Species in the model can exist in multi-
ple states and locations. The Narrative Language can
therefore be employed to model any biological process
involving state transitions of different types; inter-molec-
ular interactions; spatial confinement and temporal evo-
lution. In order to assess the generalisability of the
approach to model other biochemical systems, we have
analysed a number of simple standard models using our
and other existing simulation approaches and we have
observed a good agreement between the results (results
not reported here). Moreover, the biochemical entities,
interactions and information which can be modelled in
the Narrative Language are very similar to the ones mod-
elled in the representation used in the NCI-Nature Path-
way Interaction Database (PID) [36], a curated collection
of biomolecular pathways represented in a graphical lan-
guage. Considered the analogies between the PID and our
proposal, we are currently developing a mapping between
the PID representation and the Narrative Language. This
translation would provide us with a significant number of
well-understood pathways which can be directly simu-
lated.
Finally the simulation results shown in this paper are
obtained using N2BB, which translates Narrative Lan-
guage models into BlenX models, but the translation of
the Narrative Language into other current or future lan-
guages is possible. Thus the biological formulation of the
pathway is separable from the computer method
employed for simulation and analysis, allowing for inter-
operability with other tools for modelling and analysis of
biochemical systems. For instance, a translation into the
Bio-PEPA process algebra [37] is currently under develop-
ment, and would allow modellers to describe models in
the Narrative Language and study them by means of the
various analysis methods usable for Bio-PEPA models
(e.g. model-checking and mathematical techniques based
on differential equations).
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